9MW1111 / Mabwell (Shanghai) Biosci - LARVOL DELTA

Two new drugs from Maiwei Biotech were returned, and the company lost more than 1 billion yuan last year [Google translation] (163.com) - "...Maiwei Bio announced that the company and its whollyowned subsidiary Taikang Biologics had entered into separate agreements with Haibo Biotech, a wholly-owned subsidiary of Yangtze River Pharmaceuticals (formerly known as: Shengsen Biopharmaceutical Co., Ltd., hereinafter referred to as 'Shengsen Biotech') signed a 'Negotiation' on the projects 9MW1111 (recombinant humanized antiPD-1 monoclonal antibody injection) and 8MW0511 (recombinant (yeast secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injection) Termination of the Agreement....Maiwei Biotech stated that the reason for being 'returned' was mainly because during the cooperation period, the market competition pattern of PD-1 products and G-CSF products changed significantly, and the market prices of the products experienced significant adjustments."

Licensing / partnership • Oncology • Solid Tumor

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=21; Recruiting; Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor